Summary
Introduction
Low concentrations of inorganic pyrophosphate (PPI) inhibit the formation of crystals of calcium phosphate (Fleisch, Russell & Straumann, 1966 ) and the growth and aggregation (Fleisch & Monod, 1973; Robertson, Peacock & Nordin, 1973 ) of crystals of calcium oxalate in uitro. Inorganic pyrophosphate may therefore be a physiological regulator of biological calcification (Russell & Fleisch, 1975) and the PPI in urine may help to prevent renal stones composed of calcium phosphate or oxalate . Excretion of PPI may be lower than normal in the urine of stone-formers (Lewis, Thomas & Tomita, 1966; Russell & Hodgkinson, 1966; Sommer-Tsilenis, Fenner, Kallistratos & Timmermann, 1967; O'Brien, Uhlemann & McIntosh, 1967) . Moreover, the marked increase in the renal excretion of PPI that follows ingestion of orthophosphate (Pi) (Fleisch, Bisaz & Care, 1964) may contribute towards the apparent ability of phosphate supplements to reduce the rate of production of renal calculi in man (Thomas & Miller, 1967; Horn, 1967; Howard, 1962; Smith, Thomas & Arnaud, 1973) . Since the mechanism by which PI causes this increase in the urinary excretion of PPI is unknown, we decided to study the effect of PI on the renal clearance of PPI in man. We have also infused 43 6 R. G. G. Russell, Sylvia Bisaz and H. Fleisch PI into single renal arteries of dogs, in order to see whether PI directly influences the renal handling of PPI.
Methods

Rerral clearmice studies in mait
Ten men convalescing from allergic pulmonary disease in Davos consented to take part. None had a history of renal or bone disease. The effects of a single oral dose of PI and of continued dosage with PI were studied in five patients for each procedure.
The single-dose study was performed by giving 24 mmol of P (as 16-8 mmol of KH2P04 plus 7.2 mmol of Na2HP04,2H20) at 09.00 hours to fasting subjects. Urine samples were collected every 30 min and refrigerated until analysis. Urine flow was augmented by 200 ml of unsweetened drink every 30 min. Venous blood samples were taken at 08.30, 10.00 and 11.30 hours.
In the continuous dosage study, clearances were measured essentially as above in the fasting state and then at 12.00 hours the subject received two capsules of the phosphate mixture orally, followed by one capsule every 3 h until the following morning at 09.00 hours. Each capsule contained 5.4 mmol of P and the total phosphorus intake in this form was therefore 48 mmol. The PI was given as a mixture of KH2P04 (33.6 mmol/day) and Na2HP04,2H20 (14.4 mmol/ day). On the second day, the procedure for clearances was similar to that on the first day but no further phosphate was given after 09.00 hours. The diet was otherwise similar on each day.
Reiral arterial infusion studies in dogs
Seven mongrel dogs, weight range 13.5-22 kg, were used. Anaesthesia was induced with intravenous pentobarbital (Nembutal, 20-30 mg/kg) and maintained either with a halothane/02 gas mixture or by constant infusion of pentobarbital (15-90 mg/h). The femoral artery was catheterized for blood sampling and a femoral or brachial vein was catheterized for an intravenous infusion of inulin (12 mglmin), paminohippurate (2.06 pmol/min) and creatinine (34 pmol/min). These substances were dissolved in NaCl soh. (155 mmol/l) infused at 6 ml/min through a multichannel constant-infusion pump. In most experiments, 10% (wlv) mannitol replaced some of the NaCl soh. on a volume-for-volume basis so that the dog received 0.5-1.5 mmol of mannitol/min. A priming injection of inulin (60 mglkg), p-aminohippuric acid (5-2 pmollkg) and creatinine (27 pmol/kg) was given. The ureters were separately catheterized, either by a transvesical extraperitoneal approach or at laparotomy. After the animals had been given 10000 units of heparin intravenously, the renal artery was catheterized by a technique described previously .
Infusion through the catheter in the renal artery was done with an LKB single-channel constantinfusion pump. During the control periods, NaCl soh. (155 mmol/l) was infused at 1 ml/min. During the test periods, solutions of PI (161 pmol/ml), dissolved in water, or PPI (various concentrations : see the Figures), dissolved in NaCl soh., were infused at the same rate.
In order t o eliminate traces of PPI from the PI solutions to be infused, the latter were prepared by boiling solutions of orthophosphoric acid for 1 h before adjusting the pH to 7.4 with NaOH. The sodium phosphate solutions were stored frozen and their PPI content was measured before use by the same isotope-dilution method as was used for the determination of PPI in plasma. This procedure was successful in reducing the PP, content to 0.009% of the total P.
Analytical methods
The following methods were used: PPI in urine (Fleisch & Bisaz, 1963) and plasma (Russell, Bisaz, Donath, Morgan & Fleisch, 1971) , by ion-exchange chromatography; PI, by reduction of phosphomolybdate complex with ascorbic acid (Bisaz, Russell & Fleisch, 1968) ; calcium, by atomic absorption spectrophotometry (Bisaz et al., 1968) ; creatinine (Bonsnes & Taussky, 1945 ), inulin (Heyrovsky, 1956 ) and p-aminohippurate (Bratton & Marshall, 1939) , by established methods.
All doses, concentrations and excretion rates of PPI and PI are expressed in terms of phosphorus. Clearances of PPI and PI were estimated assuming each was 100% ultrafiltrable, and that of calcium assuming it was 60% ultrafiltrable. Previous studies with PPI suggest that less than 20% is bound to plasma proteins (Russell et al., 1971) . 7.9 + 1.7 (SE) ml/min, and the mean clearance ratio of PPI to creatinine was 0.08 k0.02 (sE). The response to increased intake of Pi is shown in Fig. 1 and Tables 1 and 2 .
Results
Effect
After ingestion of a single dose of 24 mmol of PI, the urinary excretion of both P, and PPI increased within 30 min and the maximum was obtained after 14-2 h (Fig. 1 ). The increase was about fourfold for Pi and about threefold for PPI. The renal clearance of both PI and PPI rose more than twofold. The clearance of creatinine decreased slightly and that of calcium markedly. Table 1 shows that P, in plasma significantly increased by about 30% (Pe 0.02) but that the PPI in plasma did not change significantly (P> 0.7).
There were significant increases in the PPJcreatinine and PJcreatinine clearance ratios.
Similar results were obtained when PI was given over 21 h instead of in one dose (Table 2) . Again, PI induced an increase in the excretion of both PI and The increase in urine PPI in response to renal arterial infusion of PI was shown to be due to PPI itself, since the 'PPI' peaks on the ion-exchange chromatographic runs could be removed by prior hydrolysis of the urine either in hot acid or with yeast inorganic pyrophosphatase. Fig. 2 and Fig. 3 show that the effect of PI on urine PPI cannot be attributed to trace amounts of PPl in the PI infusion solution. Isotope-dilution analysis had shown that the infusion solution of PI used in these experiments contained 0.009% of the total P in the form of PPI. Infusion of PPI at an equivalent rate, i.e. 7.25 nmol of PPJmin, into the left kidney caused no change in PPI excretion from either kidney (Fig. 3) , whereas the infusion of PI itself at 161 prnol/min increased the excretion of PPI from the infused kidney approximately twofold. Infusion of PPl at a rate ten times higher (72.5 nmol/min) into the left kidney also had a negligible effect on the urinary excretion of PPI in one experiment (Fig. 3) , but in the other induced an appreciable rise in PP1 excretion (Fig. 2) . Only infusion of PPI at a rate of 0.8 pmol/min, i.e. at a concentration more than 100 times the amount present in the PI solution, caused a marked rise in PPI excretion from the infused but not from the non-infused kidney (Fig. 2) . Effect on urine PPI of intravenous injection and infusion of PP,, and the response to renal arterial infusion ofPl during intravenous infusion ofPPl. In the experiment shown in Fig. 3, 6 h after beginning the experiment a priming solution containing 80 pmol of PP1 was injected intravenously and this was followed by a continuous intravenous infusion of PP, at 1 pmol/min. The plasma concentration of PPI was not measured in these experiments because of the haemodynamic consequences of withdrawing the large volumes of blood necessary for the analysis. However, other studies in dogs (Jung, Russell, Bisaz, Morgan & Fleisch, 1970) have shown that the plasma concentration of PPI is directly related to the rate of infusion and rises to reach a new plateau concentration about 2 pmol/l higher than the previous concentration for each pmol of PPI infused/min. The plasma concentration of PP, would therefore have been expected to double in this experiment. In spite of this, only very little of the infused PPI appeared in the urine. Thus, in the hst 10 min after the priming dose of 80 pmol of PPi, only 1.2 pmol of PPI appeared in the urine. After 20 min the total excretion rate was about 0.01 5 pmol/min above the pre-infusion rate, meaning that less than 2% of the amount infused was being excreted in the urine. Fig. 4 illustrates similar results in another dog which also received PPI intravenously. In this case, considerably less than 1 % of the injected or infused PPI appeared intact in the urine. Even infusion of PP1 directly into the renal artery was not accompanied by a much higher rate of excretion. In the dog shown in Fig. 2 , the maximum rate of excretion of PPI infused at 0.8 pmol/min in the left renal artery was 2.9%. In dogs receiving systemic infusions of PPI (Fig. 3  and Fig. 4) , the response to renal arterial infusion of PI (161 fimol/min) was much more striking than in the animals not receiving PPI intravenously. The increment in urine PP1 was now several times greater than before the systemic infusion of PPI was started. The response from the infused kidney was again greater than from the non-infused kidney. In contrast to the effect on urine PPI, the rise in urine PI was less than before, probably because, with successive renal arterial infusions of PI at 161 pmollmin, glomerular filtration diminished (see the changes in inulin in Fig. 4). about 8% of the presumed filtered load of PPI was excreted in the urine under fasting conditions. The remaining 92% of the PPI was therefore either reabsorbed and/or hydrolysed in the kidney.
When the intake of PI was increased, the percentage of excreted PPI increased from an average of 8% to 29% of the presumed filtered load. The concentration of PPI in plasma, however, did not change significantly or consistently after the ingestion, of PI, in spite of the large increase in urinary PPI. Attempts to reduce the abnormally high plasma PPI in hypophosphatasia by feeding with PI (Bongioi vanni, Album, Root, Hope, Marino & Spencer, 1968 ) is therefore unlikely to be successful. Since oral PI increases urinary PP1 with little change in plasma PP1, there is probably a direct effect of PI on the renal handling of PPI. The renal arterial infusion studies in dogs support this.
In all dogs studied, the infusion of PI into one renal artery caused a greater increase in urinary PPI from the infused than from the non-infused control kidney, suggesting that PI directly affects the renal handling of PPI. The effect of renal arterial infusion of PI on urine PPI could not be attributed to trace amounts of PPl in the infusion solutions, nor did it seem likely to be due to the stimulation of secretion of parathyroid hormone, which occurs during PI infusion, since this would have been expected to produce an equal effect on each kidney. Secretion of parathyroid hormone may, however, account for part of the fall observed in calcium clearance in the human studies (Fig. 1) .
The observation that the renal effect of PI on PPI excretion was greater when the animal was receiving exogenous PPI intravenously suggests that the effect is not due to increased renal synthesis of PPI induced by phosphate, but that PI in some way alters the handling by the kidney of PPI delivered to it via !he blood. The' most likely explanations aie that PI either diminishes the tubular reabsorption of PP1 or diminishes its intrarenal hydrolysis. Either mechanism could explain most of the known facts about the renal handling of PPI. Thus there is a close and direct relation between urinary PPI and PI under a< variety of circumstances (Fleisch & Bisaz, 1963; Russell & Hodgkinson, 1966; Russell & Fleisch, 1973) , even though there is no chemical interconver: sion of the two in urine (Russell, Wadstrom, Lindstedt, Care, Bisaz & Fleisch, 1969) . If PPI and PI did share a common renal tubular transport mechanism for reabsorption, then the amount of PPI reabsorbed
Discussion
In the present studies in man, an average of only would be inversely related to tubular concentrations of PI, which would therefore, in turn, be directly related to the amount of PPI in urine. However, there is at present no direct evidence for a common tubular transport mechanism for PPI and PI, so that an effect of PI on PPI hydrolysis is also possible.
It does seem that at least some intrarenal hydrolysis of PPI to PI takes place. Thus, after intravenous injections of 32P-labelled PP,, it can be shown that at least part of the 3ZP-labelled PI appearing in urine probably arises from hydrolysis of ["'PIPPI to ["'PIPl in the kidney (Jung et a]., 1970) . PI is known to be a competitive inhibitor of alkaline phosphatases (Fernley & Walker, 1967) , enzymes which are now recognized to be pyrophosphatases. PI might therefore enhance the urinary excretion of PPI by inhibiting pyrophosphatases within the kidney. If these enzymes were active on the luminal surfaces of the tubular cells, where they can be demonstrated histochemically, then the tubular concentration of PI could directly influence the amount of PP1 appearing in urine.
It is worth noting that after intravenous injection or infusion of PPI, only a very small amount of the PPI was excreted intact into the urine. Studies on the disappearance of small amounts of ["'PIPPI injected intravenously in dogs have shown that plasma PPI is subject to a high rate of metabolic turnover and confirm that urinary excretion constitutes only a minor route for the disappearance of PPI fromplasma (Jung et al., 1970) . In view of this high turnover, it is unlikely that the small amounts of PPI that could be derived from resorption of bone could comprise a major portion of the PPI excreted daily in urine, as was at one time thought (Avioli, McDonald & Singer, 1965; Avioli, McDonald, Henneman & Lee, 1966) . The major part of the PPI in body fluids is more likely to arise as a by-product of the many biosynthetic reactions that produce PPI during pyrophosphorylysis of nucleotide triphosphates (Kornberg, 1962) .
